Stocks and Investing Stocks and Investing
Wed, February 14, 2024
Tue, February 13, 2024
Mon, February 12, 2024

David Amsellem Upgraded (TEVA) to Buy and Increased Target to $19 on, Feb 12th, 2024


Published on 2024-10-28 08:53:35 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Buy and Increased Target from $12 to $19 on, Feb 12th, 2024.

David has made no other calls on TEVA in the last 4 months.



There are 5 other peers that have a rating on TEVA. Out of the 5 peers that are also analyzing TEVA, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Monday, February 5th, 2024


These are the ratings of the 4 analyists that currently disagree with David


  • Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $17 on, Monday, February 5th, 2024
  • Glen Santangelo of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $14 on, Tuesday, January 23rd, 2024
  • Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $13 on, Monday, December 18th, 2023
  • Ashwani Verma of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $13 on, Monday, November 27th, 2023